Regeneron Reports Phase 3 extension Data for Evolocumab in Chronic kidney disease

Regeneron today announced Phase 3 extension results for evolocumab in patients with chronic kidney disease. The study demonstrated that evolocumab demonstrates safety and tolerability compared to standard of care or placebo. These results provide important insights into the treatment of chronic kidney disease and support the continued development of evolocumab in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.